Strategies for immunotherapy of cancer
Authors:
- Cornelis J.M. MeliefCMCornelis J.M. Melief
- Renée.M. ToesRTRenée.M. Toes
- Jan Paul MedemaJMJan Paul Medema
- Sjoerd H. Van Der BurgSBSjoerd H. Van Der Burg
- Ferry OssendorpFOFerry Ossendorp
- Rienk OffringaRORienk Offringa
- 1 January 2000
- book chapter
- Published by Elsevier
- Vol. 75, 235-282
Abstract
No abstract availableThis publication has 219 references indexed in Scilit:
- Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancerInternational Journal of Cancer, 1998
- Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoireEuropean Journal of Immunology, 1998
- Much ado about minor histocompatibility antigensImmunology Today, 1998
- Resistance of cultured peripheral T cells towards activation‐induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death‐inducing signaling complexEuropean Journal of Immunology, 1997
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Apoptosis by Death FactorCell, 1997
- Harnessing self-reactivity in cancer immunotherapySeminars in Immunology, 1996
- A Single Residue Exchange Within a Viral CTL Epitope Alters Proteasome-Mediated Degradation Resulting in Lack of Antigen PresentationImmunity, 1996
- A new foreign policy: MHC class I molecules monitor the outside worldImmunology Today, 1996
- A role for CD95 ligand in preventing graft rejectionNature, 1995